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Abstract
Background: Trials are robust sources of data for clinical practice; however, trial outcomes may not reflect what is
important to communicate for decision-making. The study compared clinicians’ views of outcomes to include in a
core outcome set for colorectal cancer (CRC) surgery, with what clinicians considered important information for
clinical practice (core information).
Methods: Potential outcome/information domains were identified through systematic literature reviews, reviews of
hospital information leaflets and interviews with patients. These were organized into six categories and used to
design a questionnaire survey that asked surgeons and nurses from a sample of CRC centers to rate the importance
of each domain as an outcome or as information on a nine-point Likert scale. Respondents were re-surveyed
(round 2) following group feedback (Delphi methods). Comparisons were made by calculating the difference in
mean scores between the outcomes and information domains, and paired t tests were used to explore the
difference between mean scores of the six outcome/information categories.
Results: Data sources identified 1216 outcome/information items for CRC surgery that informed a 94-item
questionnaire. First-round questionnaires were returned from 63/81 (78 %) of centers. Clinicians rated 76/94 (84 %)
domains of higher importance to measure in trials than information to communicate to patients in round 1. This
was reduced to 24/47 (51 %) in round 2. The greatest difference was evident in domains regarding survival, which
was rated much more highly as a trial outcome than an important piece of information for decision-making
(difference in mean 2.3, 95 % CI 1.9 to 2.8, p <0.0001). Specific complications and quality-of-life domains were rated
similarly (difference in mean 0.18, 95 % CI −0.1 to 0.4, p = 0.2 and difference in mean 0.2, 95 % CI −0.1 to 0.5, p = 0.
2, respectively).
Conclusions: Whilst clinicians want to measure key outcomes in trials, they rate these as less important to
communicate in decision-making with patients. This discrepancy needs to be explored and addressed to maximize
the impact of trials on clinical practice.
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Background
Clinical trials are a robust source of data to inform clinical
decision-making. There are, however, some well described
weaknesses that may undermine the interpretation of trial
results. Heterogeneous measurement and reporting of
outcomes, for example, can make cross-study compari-
sons difficult, hinder meta-analysis and lead to outcome-
reporting bias. Such problems can be minimized through
the establishment of a core outcome set (COS): a mini-
mum set of outcomes that key stakeholders agree are to
be measured in all trials in a particular field [1]. Many
COSs have now been developed, and the benefits have
been embraced internationally by research funders [1],
regulatory bodies [2, 3] and journal editors [4]. Theoretic-
ally, these outcomes represent the most important aspects
of an intervention and, therefore, may represent the most
important issues to discuss with patients.
Communicating with patients is, however, challenging.
High-quality patient-centered information is a priority for
health care providers in many countries and settings [5–7],
and patients generally prefer more rather than less informa-
tion [8], although it is difficult to know how much is
enough for an individual. One solution is to discuss very
detailed information, but this may be counterproductive by
overwhelming patients and reducing their understanding
[9]. Patient-led communication, where discussions are
guided by the individual, is helpful but patients may lack
sufficient baseline knowledge to ask important questions.
One method for addressing the balance between over- and
under-disclosure of information is to develop a core infor-
mation set (CIS) for a specific treatment. Core information
represents baseline information, determined by patients
and clinicians, that is necessary to stimulate further patient-
centered communication [10–12]. Core information sets
are now being developed in several clinical areas [11, 13].
It is hypothesized that core outcomes for trials will
correspond to core information for communication in
decision-making. The rationale for this is that if an out-
come is considered essential to measure in a trial, then
it provides information of sufficient value to use in clin-
ical practice. Similarly, if information is necessary to
communicate to patients then high-quality data support-
ing that information is best obtained from a well-
designed and well-conducted randomized trial. This has
not been previously explored. The aim of this study is to
compare clinicians’ views of outcomes to include in a
COS with what they consider important information for
clinical practice, using colorectal cancer (CRC) surgery
as an example.
Methods
This substudy was embedded within a wider program of
research to develop core outcome and information sets
for CRC surgery. The scope of the COS was to agree on
a minimum standard of outcomes for clinical effective-
ness trials (rather than trials of treatment efficacy) of all
surgical interventions for cancer of the colon and rec-
tum. The scope of the CIS was to agree on a minimum
standard of information of importance to patients and
clinicians to discuss for informed consent for CRC sur-
gery. Informed consent for recruitment to trials was not
considered. Informed consent is defined by Beauchamp
and Childress’ model of “autonomous authorization,”
which includes the discussion of what surgeons consider
to be “important” information.
The development of the core outcome and information
sets was conducted according to established guidelines
[1]. Phase 1: a long list of outcomes that could be mea-
sured in colorectal cancer trials, and information to com-
municate for consent, was identified and outcomes were
categorized into domains. Phase 2: domains were opera-
tionalized into a questionnaire that was used to survey
stakeholders’ views on the importance of each domain
using Delphi methods. Phase 3: clinicians’ views on im-
portant outcomes for trials were compared with clinicians’
and patient’s views on important information for consent.
Appropriate ethics regulatory approval was granted (Na-
tional Research Ethics Service number 10/H0102/82,
reviewed by South West 4 Research Ethics Committee).
Phase 1– Domain generation
Colorectal cancer surgical outcomes and information
were identified from three sources: (1) systematic
review of clinical- and patient-reported outcome litera-
ture [14, 15], (2) interviews with patients, and (3) ana-
lysis of written patient information leaflets used for
colorectal surgery in UK hospitals. Duplicates were re-
moved and a long list of outcomes/information was
created. Similar outcomes/information were categorized
into domains by the following process. The long list
was read and re-read to facilitate immersion in these
data. Categorization was conducted on an iterative
item-by-item basis using the principles of constant
comparison, whereby each new item was compared
with those before it and placed in what was considered
an appropriate category. Categories were changed, or
items re-categorized appropriately, as new items were
considered. After independent categorization, results
were compared and discrepancies highlighted. Patient-
reported outcomes were grouped into domains (e.g.,
ability to walk and activity levels were grouped within
the physical function domain) and verified by two re-
searchers and a patient representative [16]. Items from
patient information leaflets were independently catego-
rized by two surgeons. Discrepancies were resolved
through discussion with the study lead. Overlapping
domains between data sources were condensed produ-
cing a final list of domains.
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Fig. 1 Example page from the questionnaire demonstrating the format and operationalization of the domains
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The final domains were operationalized into question-
naire items using lay language with the medical termin-
ology included in parentheses (Fig. 1). Domains were
grouped into six categories: CRC-specific complications,
general complications, operation and hospital stay, sur-
vival/recurrence, symptoms, and quality of life. The
questionnaire was piloted by patients for face validity,
understanding and acceptability and modified as a result
of this feedback.
Phase 2 – Delphi process
The questionnaire developed in phase 1 was sent to
CRC surgeons and clinical nurse specialists (round
1). Oncologists were excluded as chemo/radiotherapy
was outside the scope of the COS/CIS. Surgeons and
nurses were identified from UK National Health Ser-
vice hospital trusts that routinely performed surgical
resection of CRC and participated in the UK Na-
tional Bowel Cancer Audit. Non-probabilistic pur-
posive sampling was conducted to ensure center
variation based upon geographical region (Northern
England, the Midlands, South West England, South
East England, and Wales), and caseload volume per
annum as determined by number of major resections
in 2012. Demographic details were collected includ-
ing age, sex and seniority (years on the UK specialist
register).
Questionnaires asked clinicians to rate the import-
ance of (1) measuring the domains in clinical trials,
and (2) discussing the domains as part of informed
consent. A nine-point Likert scale was used, where 1
was “not essential,” and 9 “absolutely essential” out-
come/information. Data from round 1 were collected
and entered into an electronic database. Domains that
were both rated between 7 and 9 (defined as “high
importance”) by over 50 % of respondents and be-
tween 1 and 3 (defined as “low importance”) by less
than 15 % were retained for round 2. The remainder
were discarded. In round 2, participants were pro-
vided with feedback from round 1 in the form of
their previous score for each domain and a mean
score from their stakeholder group. In addition, some
participants were also provided with feedback from
both stakeholder groups separately (details of this ex-
ploratory substudy will be described separately). Par-
ticipants were then asked to rescore each domain on
the same nine-point Likert scale. Separate written in-
formed consent was obtained from all participants.
Fig. 2 Scatter plot of mean information and mean outcome scores in round 1 with line of equality
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Phase 3 – Comparison of clinicians’ views of outcomes
and information
Clinicians’ scores from rounds 1 and 2 were collated and
the mean score calculated for each outcome and infor-
mation domain. The difference between these means
were then calculated and the domains ranked accord-
ingly. Paired t tests were used to compare mean out-
come and information scores of the six domain
categories and as an overall score.
Sample size
There are no agreed methods to set the sample size for
Delphi surveys. Therefore, an opportunistic approach
was used with the aim of obtaining approximately 100
respondents for the survey.
Results
Phase 1 – Domain generation
Review of all data sources identified 1216 outcomes of
CRC surgery that were grouped into 100 domains. A
total of six were considered only relevant to information,
not trials (for example, “the risk of family members de-
veloping bowel cancer”) and were excluded from this
analysis.
Phase 2 – Delphi process
A total of 81 CRC centers were sampled, of which 63
(78 %) responded including 90 surgeons and 8 clinical
nurse specialists (Table 1). The centers represented all
geographical regions of England and Wales, and case-
load averaged 117 major resections per year (range 38 to
275). A total of 47 domains met the criteria to be
retained for round 2. The response rate in round 2 was
80 % (78/98).
Phase 3 – Comparison of clinicians’ views of outcomes
and information
In the first survey, clinicians considered most domains
(76/94; 81 %) of greater importance to measure as trial
outcomes than to communicate to patients (Fig. 2). The
greatest difference was with the number of lymph nodes
harvested during the operation (difference in mean 4.1,
95 % CI 3.5 to 4.7), unplanned re-admission to hospital
(difference in mean 3.1, 95 % CI 2.5 to 3.6) and survival
(difference in mean 2.8, 95 % CI 2.2 to 3.4). Of the 18
domains that were considered more important to com-
municate to patients than to measure in trials, rates of
superficial surgical site infection (difference in mean
−0.9, 95 % CI −1.1 to −0.5) and the need for a stoma
(difference in mean −0.7, 95 % CI −0.9 to −0.4) showed
the greatest difference. Paired t tests demonstrated that
generic complications, the operation and hospital stay,
survival/recurrence and symptom domain categories
were all scored significantly higher as outcomes in trials
rather than information for clinical practice (Table 4).
The overall effect was that clinicians rated outcomes
higher than information (difference in mean 0.7, 95 % CI
0.4 to 0.9, p <0.0001).
Results of the second survey were moderated com-
pared to round 1. Only 24/47 (51 %) outcome domains
were rated higher than the corresponding information
domains. The greatest difference was still evident in the
number of lymph nodes harvested during the operation
(difference in mean 3.4, 95 % CI 2.8 to 4.0), survival (dif-
ference in mean 2.5, 95 % CI 1.9 to 3.0) and unplanned
re-admission to hospital (difference in mean 2.4, 95 %
CI 1.9 to 3.0). Paired t tests demonstrated that outcomes
regarding the operation and hospital stay, and survival/
recurrence remained more important than information
on the same topics. In this round, clinicians thought
CRC-specific complications were more important as in-
formation to discuss with patients then outcomes of tri-
als, but the difference was small (difference in mean
−0.3, 95 % CI −0.5 to −0.1, p <0001). The overall effect
favored outcomes rather than information (Table 4).
Table 1 Participant characteristics
Clinical centers
Responders (63) Non-responders (18)
Region (%)
Northern England 14 (22) 5 (28)
Midlands 8 (13) 0
South East England 22 (35) 10 (55)
South West England 9 (14) 0
Wales 10 (16) 3 (17)
Mean number of major
colorectal resections (range)a
117 (38 to 275) 90 (29 to 210)
Participants
Responders (94)
Male sex (%) 70 (75)
Post held (%)
Surgeon 86 (91)
Nurse 8 (9)
Time in post (%)
<5 years 12 (14)
5 to 10 years 24 (28)
>10 years 49 (58)
Age
31–40 8 (9)
41–50 48 (51)
51–60 34 (36)
Over 60 4 (4)
aNumber of major cancer resections are defined by the UK National Bowel
Cancer Audit 2012
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Discussion
This study demonstrated that clinicians consistently
rated several health outcome domains as more im-
portant to measure in trials than to use as informa-
tion provision for clinical decision-making with
patients. The effect was most pronounced in the first
survey round (which does not show views of others)
where significant differences were observed regarding
outcomes relating to the operation and hospital stay,
and survival/recurrence. In the second survey (where
views of patients and other health professionals are
presented for the participant to re-score the domains)
the effect was similar although attenuated. It is pos-
sible that health professionals’ really value trial out-
comes differently to those of importance for use for
decision-making. In which case, it is important to
consider whether trial outcomes should be more rep-
resentative of information that is valued. Findings also
suggest that clinicians’ value outcomes that they find
difficult to discuss with patients, in which case train-
ing in communication and shared decision-making is
required. These discrepancies are important to ex-
plore further to maximize the impact of trials on clin-
ical practice.
It has not been possible to identify previous studies
that have directly compared clinician’s views on
outcomes for trials and views on information for clinical
practice. A recent study, however, has developed a CIS
for oesophageal cancer surgery [11]. Detailed compari-
sons with this work were not possible because only lim-
ited data are presented in the publication; however,
clinicians’ views appear to be similar to those found
here. Operation-specific complications, such as anasto-
motic leak, and peri-operative mortality were rated
highly, and long-term survival information did not fea-
ture in the top 20 issues of importance to clinicians. The
reasons for these findings are not clear. Multiple previ-
ous studies have shown that cancer patients have de-
tailed and broad information needs, especially regarding
issues of prognosis [8]. A survey of 2300 cancer patients
in the UK, for example, demonstrated that over 95 %
wanted to know survival statistics [17]. Clinicians’ views
appear discordant with this evidence. It may be that cli-
nicians consider the information upsetting for patients
or difficult to understand. Perhaps clinicians value the
data generated from randomized trials to make treat-
ment recommendations, but do not consider it import-
ant to discuss with patients.
It has been widely recognized that patients and profes-
sionals differ with regards to what outcomes are consid-
ered important to measure in clinical trials. Core
outcome set development was first pioneered in the field
Table 2 The 20 domains with the greatest difference between mean outcome and information scores in round 1
Domain name Category Mean outcome score Mean information score Difference in mean 95 % CI
Lymph node harvest Operation and hospital stay 7.89 3.85 4.07 3.46 to 4.68
Unplanned re-admission Operation and hospital stay 7.94 4.90 3.06 2.52 to 3.61
Long-term survival Survival/recurrence 7.76 4.95 2.81 2.21 to 3.41
Disease-free interval Survival/recurrence 7.47 4.78 2.72 2.13 to 3.30
Length of hospital stay Operation and hospital stay 7.77 5.45 2.35 1.83 to 2.88
Second primary cancer Survival/recurrence 5.58 3.31 2.27 1.67 to 2.88
Length of bowel removed Operation and hospital stay 5.23 3.07 2.16 1.57 to 2.75
Distant recurrence Survival/recurrence 8.02 5.93 2.11 1.57 to 2.64
Operative time Operation and hospital stay 5.94 3.84 2.07 1.54 to 2.61
Local recurrence Survival/recurrence 8.07 6.00 2.04 1.54 to 2.55
Recurrence Survival/recurrence 8.03 6.06 1.99 1.49 to 2.49
Length of time after
surgery until the bowels open
Operation and hospital stay 6.08 4.15 1.98 1.46 to 2.50
Equipment failure Operation and hospital stay 4.86 3.08 1.79 1.21 to 2.37
Reoperation Operation and hospital stay 8.24 6.61 1.64 1.16 to 2.11
Resection margins Operation and hospital stay 8.55 6.97 1.60 1.06 to 2.14
Non-progression Operation and hospital stay 7.71 6.15 1.56 1.06 to 2.07
Multi-organ failure Generic complications 6.83 5.34 1.55 1.03 to 2.07
Allergic reactions Generic complications 4.66 3.21 1.45 0.87 to 2.03
Enterocutaneous fistula CRC-specific complications 6.03 4.66 1.39 0.88 to 1.90
Enterovisceral fistula CRC-specific complications 5.68 4.36 1.27 0.78 to 1.76
McNair et al. Trials  (2016) 17:344 Page 6 of 9
of rheumatology, where the OMERACT (Outcome Mea-
sures in Rheumatology) initiative started using consen-
sus methodology to enable professionals to agree on
which outcomes to measure in trials. This was initially a
closed process, but it was opened up to patients after
6 years. Patients identified three outcome domains that
were not considered important by professionals (fatigue,
sleep disturbance and arthritic “flairs”) and these were
subsequently included in the core set. Although not ex-
plicit, it is likely that patients were interested in discuss-
ing these trial outcomes in clinical consultations. This is,
however, the first study to directly measure the internal
discrepancies between what clinicians want to measure
in trials and what they want to communicate to patients.
Methods used in this study followed guidelines estab-
lished by the Core Outcome Measures in Effectiveness
Trials (COMET) initiative to develop a COS, but there
are some weaknesses. The validity of including specific
outcome/information domains in the questionnaires can
be criticized; however, this has no impact on the com-
parative importance that clinicians and patients place on
such outcomes/information. Rather, it represents a limi-
tation of the development of the COS. Another limita-
tion is that the findings may represent a failure in
methodology and, in particular, the way the question-
naire was presented may have biased responses. For ex-
ample, participants were asked to rate domains as
outcomes before rating them as information for
decision-making. This may have induced the
prioritization of the former over the latter. Similarly, the
order of the domains within the questionnaire may have
had an impact on responses. Domains regarding quality
of life came at the end of the questionnaire, and thus
may have been seen as of lower priority. This, however,
should not have influenced the comparative scores of in-
dividual domains. Descriptive statistics were used to
summarize domain scoring, and multiple hypothesis
testing was avoided. Caution should be exercised, how-
ever, when comparing individual domain scores because
of issues of multiplicity.
Further research is needed to understand the implica-
tions of this study. Understanding why clinicians rate
these outcome and information domains differently is
critical. Qualitative interviews with clinicians and trial-
lists would provide a framework for exploring these is-
sues. It is also important to understand the impact of
integrating patients’ views of outcome and information
into core set development. It may be that patients’ views
Table 3 The 20 domains with the greatest difference between mean outcome and information scores in round 2
Domain name Category Mean outcome score Mean information score Difference in mean 95 % CI
Lymph node harvest Operation and hospital stay 7.79 4.40 3.36 2.75 to 3.97
Long-term survival Survival/recurrence 7.91 5.42 2.45 1.94 to 2.96
Unplanned re-admission Operation and hospital stay 7.82 5.37 2.41 1.87 to 2.96
Disease-free interval Survival/recurrence 7.57 5.13 2.39 1.84 to 2.95
Local recurrence Survival/recurrence 8.04 6.13 1.90 1.40 to 2.40
Recurrence Survival/recurrence 8.08 6.23 1.86 1.34 to 2.38
Length of hospital stay Operation and hospital stay 7.51 5.63 1.86 1.33 to 2.38
Distant recurrence Survival/recurrence 8.03 6.31 1.70 1.18 to 2.23
Length of bowel removed Operation and hospital stay 4.88 3.29 1.60 1.00 to 2.20
Length of time after
surgery until the bowels open
Operation and hospital stay 5.77 4.36 1.43 0.93 to 1.93
Non-progression Operation and hospital stay 8.03 6.57 1.43 0.93 to 1.93
Resection margins Operation and hospital stay 8.70 7.36 1.33 0.91 to 1.75
Reoperation Operation and hospital stay 8.08 7.01 1.04 0.63 to 1.46
Length of time after
surgery to start eating
and drinking
Operation and hospital stay 6.25 5.47 0.80 0.33 to 1.27
Overall quality of life Quality of life 6.61 5.97 0.66 0.30 to 1.02
Operative blood loss Generic complications 6.32 5.73 0.61 0.12 to 1.09
Operative mortality Operation and hospital stay 8.69 8.11 0.57 0.20 to 0.95
Overall health Quality of life 5.78 5.37 0.43 0.02 to 0.84
General pain Symptoms 6.04 5.89 0.17 −0.22 to 0.55
Conversion to open
operation
Operation and hospital stay 7.67 7.61 0.07 −0.16 to 0.31
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mitigate some of the discrepancies evident in this study,
but others may become apparent. Research is then
needed to identify methods to harmonize the measure-
ment of outcomes in trials and their use in clinical
practice.
Conclusion
This study demonstrates that whilst clinicians want to
measure key outcomes in trials, they rate these as less
important communication in decision-making with pa-
tients. This discrepancy needs to be explored and ad-
dressed to maximize the impact of trials on clinical
practice.
Abbreviations
CI, confidence interval; CIS, core information set; COS, core outcome set;
CRC, colorectal cancer
Acknowledgements
We would like to thank Claudette Blake for her administrative support
throughout the whole project.
Funding
This work was supported by the MRC ConDuCT-II Hub (Collaboration and
innovation for Difficult and Complex randomized controlled Trials In Invasive
procedures – MR/K025643/1). RNW was supported by an NIHR doctoral re-
search fellowship.
Availability of data and materials
Not applicable.
Authors’ contributions
AGKM, STB, RNW, KNLA and JMB contributed to the study conception,
design, data acquisition, analysis, interpretation and drafting the manuscript.
ROF, JR, JEJ, GS, AMP, MGT, PAS, AR, AO, DM, RK, DGJ, RH, SJD, MGC, MC and
JB contributed to the data acquisition, analysis, and interpretation. RM
contributed to the study design, data acquisition, analysis, interpretation and
drafting the manuscript. RHux contributed to the study design, data
acquisition, analysis and interpretation. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests. This report is
independent research arising from a Clinical Fellowship supported by the
National Institute for Health Research. The views expressed in this
publication are those of the authors and not necessarily those of the NHS,
the National Institute for Health Research or the Department of Health. The
authors have no competing interest to declare.
Ethics approval and consent to participate
This study was approved by the South West 4 Research Ethics Committee
(number 10/H0102/82) and all participants provided written informed
consent.
Author details
1Centre for Surgical Research, School of Social and Community Medicine,
University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK.
2Division of Surgery Head and Neck, University Hospitals Bristol NHS
Foundation Trust, Bristol, UK. 3Colorectal Cancer Patient Representative, North
Bristol NHS Trust, Bristol, UK. 4Department of General Surgery, North Bristol
NHS Trust, Bristol, UK. 5Severn School of Surgery, Bristol, UK. 6Colorectal
Surgery Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
7Colorectal Consumer Liaison Group, National Cancer Research Institute,
London, UK. 8Academic Department of Surgery, University of Birmingham,
Birmingham, UK. 9Department of Surgery, St Mark’s Hospital and Academic
Institute, Harrow, UK. 10Academic Surgical Unit, St James’ University Hospital
NHS Trust, Leeds, UK. 11Centre for Ethics in Medicine, University of Bristol,
Bristol, UK. 12Colorectal Site Specific Group, Somerset, Wiltshire, Avon and
Table 4 Comparison of mean outcome and information scores for domain categories
Round 1
Domain category Number of
domains
Mean outcome
score
Mean information
score
Difference in
means
SD 95 % CI P valuea
CRC-specific complications 14 6.17 5.99 0.18 1.29 −0.08 to 0.44 0.18
Generic complications 17 5.41 4.82 0.59 1.70 0.25 to 0.93 0.001
Operation and hospital
stay
15 7.09 5.39 1.70 1.50 1.40 to 2.00 <0.0001
Survival/recurrence 6 7.49 5.15 2.34 2.28 1.88 to 2.80 <0.0001
Symptoms 29 4.55 4.27 0.29 1.29 0.03 to 0.55 0.03
Quality of life 13 5.26 5.06 0.20 1.68 −0.14 to 0.54 0.24
Overall 94 5.65 4.99 0.66 1.12 0.43 to 0.88 <0.0001
Round 2
CRC-specific complications 6 7.44 7.74 −0.30 0.77 −0.48 to
−0.12
<0.0001
Generic complications 5 6.48 6.66 −0.17 1.48 −0.52 to 0.18 0.32
Operation and hospital
stay
12 7.40 6.07 1.33 1.20 1.04 to 1.62 <0.0001
Survival/recurrence 5 7.90 5.84 2.06 1.98 1.59 to 2.53 <0.0001
Symptoms 10 5.76 6.00 −0.24 1.16 −0.52 to 0.03 0.08
Quality of life 9 5.62 5.66 −0.04 1.28 −0.34 to 0.26 0.80
Overall 47 6.66 6.23 0.44 0.87 0.23 to 0.64 0.0001
aPaired t test
McNair et al. Trials  (2016) 17:344 Page 8 of 9
Gloucestershire, South West Cancer Network, Taunton, UK. 13Centre for
Statistics in Medicine and Oxford Clinical Trials Research Unit, Nuffield
Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
University of Oxford, Oxford, UK. 14Department of Colorectal Surgery,
Plymouth Hospitals NHS Trust, Plymouth, UK. 15Clinical Trials Research Unit,
University of Leeds, Leeds, UK.
Received: 28 December 2015 Accepted: 7 July 2016
References
1. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E,
Tugwell P. Developing core outcome sets for clinical trials: issues to
consider. Trials. 2012;13:132.
2. US Department of Health and Human Services, Food and Drug
Administration. Guidance for Industry Clinical Development Programs for
Drugs, Devices, and Biological Products for the Treatment of Rheumatoid
Arthritis (RA). 1999. http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM071579.pdf.
3. The European Agency for the Evaluation of Medicinal Products. Guideline
on clinical investigation of medicinal products other than NSAIDs for
treatment of rheumatoid arthritis. London; 2003. http://www.emea.europa.
eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500003439.pdf.
4. Khan K. The CROWN Initiative: journal editors invite researchers to develop
core outcomes in women’s health. Midwifery. 2014;30:1147–8.
5. Epstein RM, Street RL. Patient-centered communication in cancer care:
promoting healing and reducing suffering. In: Patient-centered
communication in cancer care: promoting healing and reducing suffering
(Editor ed.^eds.), vol. NIH Publication No. 07-6225. City: National Cancer
Institute; 2007.
6. Department of Health. The NHS constitution for England. London; 2009.
7. Australian Commission on Safety and Quality in Health Care. Patient centred
care: improving quality and safety through partnerships with patients and
consumers. Sidney: ACSQHC; 2011.
8. Rutten LJ, Arora NK, Bakos AD, Aziz N, Rowland J. Information needs and
sources of information among cancer patients: a systematic review of
research (1980–2003). Patient Educ Couns. 2005;57:250–61.
9. Leydon GM, Boulton M, Moynihan C, Jones A, Mossman J, Boudini M,
McPherson K. Cancer patients’ information needs and information seeking
behaviour: in depth interview study. BMJ. 2000;320:909–13.
10. Beauchamp TL, Childress JF. Respect for autonomy. In: Principles of
biomedical ethics. 5th ed. Oxford: Oxford University Press; 2001. p. 57–112.
11. Blazeby JM, Macefield R, Blencowe NS, Jacobs M, McNair AG, Sprangers M,
Brookes ST, Research, Consensus Groups of the Core Outcomes and
iNformation SiSSOC, et al. Core information set for oesophageal cancer
surgery. Br J Surg. 2015;102:936–43.
12. Main BG, Davies L, McNair A, Blazeby JM. Bringing informed consent back
to patients. BMJ. 2015. http://blogs.bmj.com/bmj/2014/08/05/barry-main-et-
al-bringing-informed-consent-back-to-patients/.
13. Developing a core information set for consent to oral cancer surgery. http://
www.hra.nhs.uk/news/research-summaries/developing-a-core-information-
set-for-consent-to-oral-cancer-surgery/. Accessed 22 July 2016.
14. Whistance RN, Forsythe RO, McNair AG, Brookes ST, Avery KN, Pullyblank AM,
Sylvester PA, Jayne DG, Jones JE, Brown J, et al. A systematic review of outcome
reporting in colorectal cancer surgery. Colorectal Dis. 2013;15:e548–60.
15. McNair A, Whistance RN, Forsythe RO, Rees J, Jones JE, Pullyblank AM, Avery
K, Brookes ST, Thomas MG, Sylvester PA, et al. Synthesis and summary of
patient-reported outcome measures (PROMs) to inform the development of
a core outcome set in colorectal cancer surgery. Colorectal Dis. 2015.
16. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST,
Sprangers MA, Blazeby JM. Developing core outcomes sets: methods for
identifying and including patient-reported outcomes (PROs). Trials. 2014;15:49.
17. Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer:
results from a large study in UK cancer centres. Br J Cancer. 2001;84:48–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
McNair et al. Trials  (2016) 17:344 Page 9 of 9
